X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Panacea Biotech with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs ACTAVIS (US) - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 PANACEA BIOTECH   ACTAVIS
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
ACTAVIS
Dec-14
PANACEA BIOTECH/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs14918,583-   
Low Rs8211,335-   
Sales per share (Unadj.) Rs84.13,346.3-  
Earnings per share (Unadj.) Rs-18.3-417.6-  
Cash flow per share (Unadj.) Rs-6.7307.0-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs83.77,258.0-  
Shares outstanding (eoy) m61.25265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.44.5 30.7%   
Avg P/E ratio x-6.3-35.8 17.6%  
P/CF ratio (eoy) x-17.248.7 -35.4%  
Price / Book Value ratio x1.42.1 66.9%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,0743,977,639 0.2%   
No. of employees `0002.821.6 12.7%   
Total wages/salary Rs m1,4490-   
Avg. sales/employee Rs Th1,874.141,193.7 4.5%   
Avg. wages/employee Rs Th527.00-   
Avg. net profit/employee Rs Th-407.7-5,140.5 7.9%   
INCOME DATA
Net Sales Rs m5,154889,783 0.6%  
Other income Rs m100-2,221 -4.5%   
Total revenues Rs m5,254887,563 0.6%   
Gross profit Rs m-766114,305 -0.7%  
Depreciation Rs m711192,671 0.4%   
Interest Rs m1,50328,065 5.4%   
Profit before tax Rs m-2,881-108,651 2.7%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,771-7,970 -22.2%   
Tax Rs m17-5,586 -0.3%   
Profit after tax Rs m-1,121-111,036 1.0%  
Gross profit margin %-14.912.8 -115.7%  
Effective tax rate %-0.65.1 -11.3%   
Net profit margin %-21.8-12.5 174.4%  
BALANCE SHEET DATA
Current assets Rs m3,810468,802 0.8%   
Current liabilities Rs m8,365341,894 2.4%   
Net working cap to sales %-88.414.3 -619.7%  
Current ratio x0.51.4 33.2%  
Inventory Days Days15658 268.4%  
Debtors Days Days6766 101.4%  
Net fixed assets Rs m14,480108,651 13.3%   
Share capital Rs m610-   
"Free" reserves Rs m9030-   
Net worth Rs m5,1271,929,908 0.3%   
Long term debt Rs m5,8321,011,310 0.6%   
Total assets Rs m19,4333,536,886 0.5%  
Interest coverage x-0.9-2.9 31.9%   
Debt to equity ratio x1.10.5 217.1%  
Sales to assets ratio x0.30.3 105.4%   
Return on assets %2.0-2.3 -83.7%  
Return on equity %-21.9-5.8 380.1%  
Return on capital %3.6-3.0 -120.8%  
Exports to sales %24.50-   
Imports to sales %10.20-   
Net fx Rs m5970-   
CASH FLOW
From Operations Rs m599152,793 0.4%  
From Investments Rs m-438-365,845 0.1%  
From Financial Activity Rs m-303205,552 -0.1%  
Net Cashflow Rs m-141-7,500 1.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 68.12 Rs / USD

Compare PANACEA BIOTECH With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare PANACEA BIOTECH With: TTK HEALTHCARE  STERLING BIOTECH  NOVARTIS  UNICHEM LAB  ALEMBIC PHARMA  



Today's Market

Sensex up 200 Points; Realty Stocks Gain(12:30 pm)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and are presently trading above the dotted line.

Related Views On News

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Jun 20, 2018 01:21 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - VENUS REMEDIES COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS